The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Open accessAbstract
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.Methods Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.Results Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).Conclusions These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Price et al., 2009
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine rapidly induces flexibility in implicit representations of self on the Implicit Association Test 134,135 , and these shifts correlated with self-reported symptom improvements 110 , suggesting that ketamine can immediately impact the structure of implicit mental representations relevant to one's concept of self, a core form of cognitive bias in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [135]
In the citing paper
“Critically, several versions of the IAT have also been incorporated into clinical ketamine trials, which found that the “escape” version of the IAT (instead of “death,” the participant links the self with “escape” or “stay”) was associated with reductions in SI (57, 58).”
From New methods for assessing rapid changes in suicide risk (2021) · cites this paper as [57]
In the citing paper
“Administration of glutamate receptor antagonists, such as the NMDA antagonist, ketamine, have potent antidepressant effects especially in treatment resistant depressed patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Price et al., 2009
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [152]
In the citing paper
“Ketamine has been also shown to induce a rapid amelioration of suicidal ideation in major depressed patients 23, 24”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Measuring individual differences in implicit cognition: the implicit association test
Greenwald, A. G., McGhee, D. E., & Schwartz, J. L. K. (1998) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.74.6.1464 · Cited by 9,210
Understanding and using the Implicit Association Test: I. An improved scoring algorithm.
Greenwald, A. G., Nosek, B. A., & Banaji, M. R. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.85.2.197 · Cited by 5,815
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationUnderstanding and using the Implicit Association Test: III. Meta-analysis of predictive validity.
Greenwald, A. G., Poehlman, T. A., Uhlmann, E. L., & Banaji, M. R. (2009) · Journal of Personality and Social Psychology · doi:10.1037/a0015575 · Cited by 3,257
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Understanding and Using the Implicit Association Test: II. Method Variables and Construct Validity
Nosek, B. A., Greenwald, A. G., & Banaji, M. R. (2004) · Personality and Social Psychology Bulletin · doi:10.1177/0146167204271418 · Cited by 1,216
Cited by
Sorted by citations
Items 201–300 of 601
Top Ten Tips Palliative Care Clinicians Should Know About Psychopharmacology
Riordan, P. A., Briscoe, J. G., Uritsky, T. J., Jones, C. A., & Webb, J. A. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0106 · Cited by 63
Lenze, E. J., Skidmore, E. R., Begley, A. E., Newcomer, J. W., Butters, M. A., & Whyte, E. M. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2813 · Cited by 63
Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder
Medina, A. M., Burke, S., Thompson, R. C., Bunney, W. E., Myers, R., Schatzberg, A. F., Akil, H., & Watson, S. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.04.007 · Cited by 67
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R. R., Zarate, C. A., & Kasper, S. F. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18205 · Cited by 64
New methods for assessing rapid changes in suicide risk
Ballard, E. D., Gilbert, J. R., Wusinich, C., & Zarate, C. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.598434 · Cited by 63
Kopelman, J., Keller, T. A., Panny, B., Griffo, A., Degutis, M., Spotts, C., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02451-0 · Cited by 60
Self-citationNew Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview
Bortolozzi, A. A., Fico, G., Berk, M., Solmi, M., Fornaro, M., Quevedo, J., Zarate, C. A., Kessing, L. V., Vieta, E., & Carvalho, A. F. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000007 · Cited by 68
Moshiri, I., Salehi, B., Mohammadbeigi, A., Kamali, A., & Taheri-nejad, M. R. (2015) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.166444 · Cited by 61
Iglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., Hirst, J. M., & Irwin, S. A. (2015) · Psychosomatics · doi:10.1016/j.psym.2014.05.005 · Cited by 60
Zhan, Y., Zhang, B., Zhou, Y., Zheng, W., Liu, W., Wang, C., Li, H., Chen, L., Yu, L., Walter, M., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.071 · Cited by 60
Duncan, W. C., Ballard, E. D., & Zarate, C. A. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2017_51 · Cited by 58
Costa, V., Lugert, S., & Jagasia, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_4 · Cited by 63
Pocivavsek, A., Schwarcz, R. M., & Erhardt, S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000239 · Cited by 63
Poleszak, E., Właź, P., Szewczyk, B., Właź, A., Kasperek, R., Wróbel, A., & Nowak, G. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0630-9 · Cited by 59
McGowan, J. C., Hill, C., Mastrodonato, A., LaGamma, C. T., Kitayev, A., Brachman, R. A., Narain, N. R., Kiebish, M. A., & Denny, C. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0043-7 · Cited by 57
Characterizing the course of suicidal ideation response to ketamine
Ballard, E. D., Yarrington, J. S., Farmer, C., Richards, E. M., Machado‐Vieira, R., Kadriu, B., Niciu, M. J., Yuan, P., Park, L., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.077 · Cited by 57
Ponton, E., Turecki, G., & Nagy, C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab082 · Cited by 59
Weckmann, K., Labermaier, C., Asara, J. M., Müller, M. B., & Turck, C. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.119 · Cited by 53
Using Implicit and Explicit Measures to Predict Nonsuicidal Self-Injury Among Adolescent Inpatients.
Cha, C. B., Augenstein, T. M., Frost, K., Gallagher, K., D'Angelo, E., & Nock, M. (2016) · Journal of the American Academy of Child and Adolescent Psychiatry · doi:10.1016/j.jaac.2015.10.008 · Cited by 49
Self-citationThe effects of ketamine on suicidality across various formulations and study settings
Dadiomov, D., & Lee, K. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.01.048 · Cited by 53
The role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52
Glenn, C. R., Kleiman, E. M., Coppersmith, D. D. L., Santee, A. C., Esposito, E. C., Cha, C. B., Nock, M. K., & Auerbach, R. P. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12769 · Cited by 54
Self-citationSubanesthetic Ketamine Reactivates Adult Cortical Plasticity to Restore Vision from Amblyopia
Grieco, S. F., Qiao, X., Zheng, X., Liu, Y., Chen, L., Zhang, H., Yu, Z., Gavornik, J. P., Lai, C., Gandhi, S. P., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.07.008 · Cited by 60
Maalouf, F. T., Porta, G., Vitiello, B., Emslie, G. J., Mayes, T. L., Clarke, G., Wagner, K. D., Asarnow, J. R., Spirito, A., Keller, M. B., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.021 · Cited by 54
Sex differences in resilience: Experiential factors and their mechanisms
Fallon, I. P., Tanner, M. K., Greenwood, B. N., & Baratta, M. V. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14639 · Cited by 62
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
Can, A., Hermens, D. F., Dutton, M., Gallay, C. C., Jensen, E., Jones, M., Scherman, J. K., Beaudequin, D. A., Yang, C., Schwenn, P., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01230-z · Cited by 53
Muscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.710338 · Cited by 59
Niciu, M. J., Grunschel, B. D., Corlett, P. R., Pittenger, C., & Bloch, M. H. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113486718 · Cited by 53
Bernstein, S. L., & D’Onofrio, G. (2013) · Health Affairs · doi:10.1377/hlthaff.2013.0664 · Cited by 57
Feeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 57
Suzuki, K., Kim, J.-W., Nosyreva, E., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109918 · Cited by 49
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740996 · Cited by 53
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51
Dahl, J., Andreassen, O. A., Verkerk, R. M., Malt, U. F., Sandvik, L., Brundin, L., & Ormstad, H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.02.011 · Cited by 51
Strong, C. E., Schoepfer, K. J., Dossat, A. M., Saland, S. K., Wright, K. N., & Kabbaj, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.003 · Cited by 49
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Ellis, T. E., Rufino, K. A., & Green, K. L. (2016) · Archives of Suicide Research · doi:10.1080/13811118.2015.1004483 · Cited by 49
Bechtholt, A. J., Smith, K. L., John, C. S., Kang, H., Carlezon, W. A., Cohen, B. M., & Öngür, D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2169-8 · Cited by 49
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 51
Sohn, M. N., McMorris, C. A., Bray, S., & McGirr, A. (2021) · Psychological Medicine · doi:10.1017/s0033291721002117 · Cited by 49
Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions
Price, R. B., & Mathew, S. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0232-4 · Cited by 51
Self-citationKetamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Zaytseva, A., Bouckova, E., Wiles, M. J., Wustrau, M. H., Schmidt, I. G., Mendez-Vazquez, H., Khatri, L., & Kim, S. (2023) · eLife · doi:10.7554/elife.86022 · Cited by 48
Juven‐Wetzler, A., Cohen, H., Kaplan, Z., Kohen, A., Porat, O., & Zohar, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.007 · Cited by 48
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 53
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
NMDA antagonists under investigation for the treatment of major depressive disorder
Pochwat, B., Pałucha-Poniewiera, A., Szewczyk, B., Pilc, A., & Nowak, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918951 · Cited by 48
Auerbach, R. P., Pagliaccio, D., & Kirshenbaum, J. S. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_358 · Cited by 51
Cunha, M. P., Pazini, F. L., Rosa, J. M., Ramos-Hryb, A. B., Oliveira‐Giacomelli, Á., Kaster, M. P., & Rodrigues, A. L. S. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9446-7 · Cited by 47
Antidepressant-like effects of a novel curcumin derivative J147: Involvement of 5-HT1A receptor
Lian, L., Xu, Y., Zhang, J., Yu, Y., Zhu, N., Guan, X., Huang, H., Chen, R., Chen, J., Shi, G., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.003 · Cited by 48
Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade
Nosyreva, E., Autry, A. E., Kavalali, E. T., & Monteggia, L. M. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00094 · Cited by 51
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 49
Pharmacogenomics of Suicidal Events
Brent, D. A., Melhem, N., & Turecki, G. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.64 · Cited by 47
Saligan, L. N., Luckenbaugh, D. A., Slonena, E. E., Machado‐Vieira, R., & Zarate, C. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.01.009 · Cited by 46
Zhang, X., He, T., Wu, Z., Wang, Y., Liu, H., Zhang, B., Yang, S., Wang, D., Huang, C., Duan, J., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.026 · Cited by 46
Ketamine and suicidal ideation in depression: Jumping the gun?
Rajkumar, R., Fam, J., Yeo, E. Y. M., & Dawe, G. S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.003 · Cited by 43
Camargo, A., Pazini, F. L., Rosa, J. M., Wolin, I. A. V., Moretti, M., da Rosa, P. B., Neis, V. B., & Rodrigues, A. L. S. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.017 · Cited by 44
Vai, B., Poletti, S., Radaelli, D., Dallaspezia, S., Bulgarelli, C., Locatelli, C., Bollettini, I., Falini, A., Colombo, C., Smeraldi, E., et al. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.07.015 · Cited by 42
Ketamine for the Treatment of Depression
Howland, R. H. (2013) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20121219-01 · Cited by 43
Toxoplasma gondii, Suicidal Behavior, and Intermediate Phenotypes for Suicidal Behavior
Postolache, T. T., Wadhawan, A., Rujescu, D., Hoisington, A. J., Dagdag, A., Baca‐García, E., Lowry, C. A., Okusaga, O. O., & Brenner, L. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.665682 · Cited by 47
Murrough, J. W., Perez, A. M., Mathew, S. J., & Charney, D. S. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06447blu · Cited by 42
Self-citationWen, G., Yao, H., Li, Y., Ding, R., Ren, X., Tan, Y., Ren, W., Yu, H. Q., Zhan, X., Wang, X., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00287 · Cited by 44
Wilkening, J., Witteler, F., & Goya‐Maldonado, R. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13502 · Cited by 43
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 41
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39
Davis, M. T., DellaGiogia, N., Maruff, P., Pietrzak, R. H., & Esterlis, I. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01327-5 · Cited by 37
Neurobiological aspects of suicide and suicide attempts in bipolar disorder
Mathews, D., Richards, E., Niciu, M., Ionescu, D., Rasimas, J., & Zarate, C. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0120-7 · Cited by 39
KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?
Wilkinson, S. T., & Sanacora, G. (2016) · Depression and Anxiety · doi:10.1002/da.22498 · Cited by 41
Pazini, F. L., Rosa, J. M., Camargo, A., Fraga, D. B., Moretti, M., Siteneski, A., & Rodrigues, A. L. S. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109281 · Cited by 39
Star-D: lessons learned and future implications
Rush, A. J. (2011) · Depression and Anxiety · doi:10.1002/da.20841 · Cited by 41
Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism
Bryleva, E. Y., & Brundin, L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_5 · Cited by 40
Current Status of Ketamine and Related Compounds for Depression
Mathews, D. C., & Zarate, C. A. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13ac08382 · Cited by 37
Ketamine as Antidepressant? Current State and Future Perspectives
Hasselmann, H. (2013) · Current Neuropharmacology · doi:10.2174/1570159x113119990043 · Cited by 37
Cracking the moody brain: Lifting the mood with ketamine
Murrough, J. W., & Charney, D. S. (2010) · Nature Medicine · doi:10.1038/nm1210-1384 · Cited by 36
Self-citationLeem, Y., Kato, M., & Chang, H. (2018) · Physical Activity and Nutrition · doi:10.20463/jenb.2018.0009 · Cited by 37
Sinyor, M., Williams, M., Belo, S., Orser, B. A., Vincent, M., Mah, L., Zarate, C. A., Castel, S., LEVITT, A. J., & Schaffer, A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.073 · Cited by 39
Sakhaee, E., Ostadhadi, S., Khan, M. I., Yousefi, F., Norouzi‐Javidan, A., Akbarian, R., Chamanara, M., Zolfaghari, S., & Dehpour, A. R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.073 · Cited by 36
Okusaga, O. O., Duncan, E., LANGENBERG, P. W., Brundin, L., Fuchs, D., Groer, M. E., Giegling, I., Stearns‐Yoder, K. A., Hartmann, A. M., Konte, B., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.002 · Cited by 35
Shah, A. P., Carreno, F. R., & Frazer, A. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.2.83 · Cited by 36
Repurposing of Drugs–The Ketamine Story
Das, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01193 · Cited by 41
Scotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 37
Hua, H., Huang, C., Liu, H., Xu, X., Xu, X., Wu, Z., Liu, C., Wang, Y. Y., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109272 · Cited by 37
Ketamine‐An Update on Its Clinical Uses and Abuses
Xu, J., & Lei, H. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12363 · Cited by 35
Factors connected with efficacy of single ketamine infusion in bipolar depression
Permoda‐Osip, A., Skibińska, M., Bartkowska‐Śniatkowska, A., Kliwicki, S., Chłopocka-Woźniak, M., & RYBAKOWSKI, J. K. (2014) · Psychiatria Polska · doi:10.12740/pp/21175 · Cited by 34
Fraga, D. B., Camargo, A., Olescowicz, G., Padilha, D. A., Mina, F., Budni, J., Brocardo, P. S., & Rodrigues, A. L. S. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109476 · Cited by 35
Feeney, A., Hock, R., Freeman, M. P., Flynn, M., Hoeppner, B., Iosifescu, D., Trivedi, M., Sanacora, G., Mathew, S., DeBattista, C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.024 · Cited by 33
Self-citationAverill, L. A., Averill, C. L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.-H., Ranganathan, M., D'Souza, D. C., Southwick, S. M., Sanacora, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.01.104 · Cited by 33
Niciu, M. J., Henter, I. D., Sanacora, G., & Zarate, C. A. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.829585 · Cited by 36
Alizadeh, N. S., Maroufi, A., Nasseri, K., Najafabadi, S. H. S., Taghiabad, A. M., Gharibi, F., & Esfandiari, G.-R. (2015) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.17795/ijpbs-1578 · Cited by 33
Kiselycznyk, C., Svenningsson, P., Delpire, E. J., & Holmes, A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.015 · Cited by 33
Traumatic Brain Injury and Suicidal Behavior: A Review
Wadhawan, A., Stiller, J. W., Potocki, E., Okusaga, O. O., Dagdag, A., Lowry, C. A., Benros, M. E., & Postolache, T. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181055 · Cited by 40
Advances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 33
Ketamine in Bipolar Disorder: A Review
Wilkowska, A., Szałach, Ł. P., & Cubała, W. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s282208 · Cited by 35
Domany, Y., & McCullumsmith, C. B. (2021) · Archives of Suicide Research · doi:10.1080/13811118.2021.1878078 · Cited by 33
Investigational drugs for treating major depressive disorder
Dhir, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267727 · Cited by 31
Viana, G. S. D. B., do Vale, E. M., de Araujo, A. R. A., Coelho, N. C., Andrade, S. M., da Costa, R. O., de Aquino, P. E. A., de Sousa, C. N. S., Medeiros, I. D. S., Vasconcelos, S. M. M., et al. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x202010107 · Cited by 31
Dysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs
Santini, E., & Klann, E. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00076 · Cited by 34
Bai, L., Hou, Y., Zhu, M., Bao, H., Nie, J., Zhang, G. Y., Shan, L., Yao, Y., Du, K., Yang, H., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv112 · Cited by 31
Metadata
- Authors
- Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Harvard University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Price, Rebecca B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 66
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC2935847
- OpenAlex
- W2118815581
- Cited by
- 600
- References
- 22
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 18 · 2023: 25 · 2022: 43 · 2021: 49 · 2020: 43 · 2019: 39 · 2018: 31 · 2017: 34 · 2016: 46 · 2015: 62 · 2014: 45 · 2013: 42 · 2012: 43
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (F31 MH081468, K23-MH-069656, MO1-RR-00071)
- National Alliance for Research on Schizophrenia and Depression
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- intravenous ketamine, treatment-resistant depression, suicidality, suicide risk, Implicit Association Test, rapid antidepressant effects, suicide assessment
- MeSH terms
- Suicide Prevention, Depression, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Suicide, Cohort Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
